Drug nanocrystals: In vivo performances.

Over the past few decades, there has been a considerable research interest in drug nanocrystal system as a pharmaceutical approach for poorly soluble drugs. At the beginning lots of works have been done to study various technologies associated with production of drug nanocrystals and their in vitro physical and chemical properties, such as morphology, formulation composition, stabilities, crystalline structure and enhanced solubility and dissolution velocity. Recently, in vivo behaviors of the nanocrystals have been generally studied in animals (including human), and the results proved that drug nanocrystals could be used as a versatile formulation to alter and improve the pharmacokinetic, pharmacodynamic and targeting properties of poorly soluble drugs. In this paper, in vivo performances of drug nanocrystals exhibited in animals in different administration route were reviewed, and the advantages of drug nanocrystals in the aspect of safety, pharmacodynamics, pharmacokinetics and targeting delivery were discussed in detail.

[1]  Gordon L. Amidon,et al.  Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size , 1996, Pharmaceutical Research.

[2]  Xueming Li,et al.  Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats , 2009, Drug development and industrial pharmacy.

[3]  L. Yahia,et al.  Therapeutic potential of nanoparticulate systems for macrophage targeting. , 2005, Biomaterials.

[4]  M. Magnani,et al.  Drug Delivery through Phagocytosis of Red Blood Cells , 2004, Transfusion Medicine and Hemotherapy.

[5]  G. Na,et al.  Physical Stability of Ethyl Diatrizoate Nanocrystalline Suspension in Steam Sterilization , 1999, Pharmaceutical Research.

[6]  R. Müller,et al.  Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908 , 1993 .

[7]  M. Dolovich,et al.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. , 2003, British journal of clinical pharmacology.

[8]  M. R. Kumar,et al.  Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives , 2011 .

[9]  I. Ashurst,et al.  Pharmaceutical evaluation of a new spacer device for delivery of metered-dose inhalers to infants and young children , 1992 .

[10]  Jiesheng Ye,et al.  Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. , 2008, International journal of pharmaceutics.

[11]  P. Uster,et al.  Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. , 2009, International journal of pharmaceutics.

[12]  James L. Little,et al.  Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS. , 2009, International journal of pharmaceutics.

[13]  Yves-Jacques Schneider,et al.  Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[14]  M. Ghorab,et al.  Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. , 2007, International journal of pharmaceutics.

[15]  Dimitra Dodou,et al.  Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  Böhm,et al.  Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. , 1999, Pharmaceutical science & technology today.

[17]  G Vergnault,et al.  Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. , 2007, Advanced drug delivery reviews.

[18]  N. Blagden,et al.  Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Po-Chang Chiang,et al.  Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. , 2008, Basic & clinical pharmacology & toxicology.

[20]  K. Johnston,et al.  In Vivo Efficacy of Aerosolized Nanostructured Itraconazole Formulations for Prevention of Invasive Pulmonary Aspergillosis , 2006, Antimicrobial Agents and Chemotherapy.

[21]  Rainer H Müller,et al.  Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  R. Müller,et al.  Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns , 2005, Journal of drug targeting.

[23]  W. Forbes,et al.  Relative Bioavailability and Effects of a High Fat Meal on Single Dose Cilostazol Pharmacokinetics , 1999, Clinical pharmacokinetics.

[24]  J. Kreuter,et al.  Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.

[25]  Rainer H. Müller,et al.  Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .

[26]  A. Weil,et al.  Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. , 2006, International journal of clinical pharmacology and therapeutics.

[27]  J. Remon,et al.  In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. , 2002, International journal of pharmaceutics.

[28]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[29]  Delie,et al.  Evaluation of nano- and microparticle uptake by the gastrointestinal tract. , 1998, Advanced drug delivery reviews.

[30]  R. Ravichandran Nanoparticles in Drug Delivery: Potential Green Nanobiomedicine Applications , 2009 .

[31]  K Borner,et al.  Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. , 2000, The Journal of antimicrobial chemotherapy.

[32]  M. Mazzotti,et al.  Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. , 2010, International journal of pharmaceutics.

[33]  Mo Li,et al.  Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs , 2009 .

[34]  Patrick Augustijns,et al.  Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. , 2008, International journal of pharmaceutics.

[35]  Jouni Hirvonen,et al.  Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods , 2010, The Journal of pharmacy and pharmacology.

[36]  Philip S Low,et al.  Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.

[37]  Jonathan Brown,et al.  Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. , 2009, International journal of pharmaceutics.

[38]  M. Odomi,et al.  Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[39]  K. Johnston,et al.  Enhanced drug dissolution using evaporative precipitation into aqueous solution. , 2002, International journal of pharmaceutics.

[40]  G Vergnault,et al.  Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound , 2005, Drug development and industrial pharmacy.

[41]  H. Gendelman,et al.  Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery , 2006, Journal of leukocyte biology.

[42]  G. Spedalieri,et al.  Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. , 2002, Biomaterials.

[43]  R. Müller,et al.  Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration , 2002, Pharmaceutical Research.

[44]  J. Dressman,et al.  In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[45]  Y. Ikada,et al.  Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. , 1999, Investigative ophthalmology & visual science.

[46]  Jonghwi Lee,et al.  Folate-targeted drug-delivery systems prepared by nano-comminution , 2011, Drug development and industrial pharmacy.

[47]  Rainer H Müller,et al.  Nanocrystal technology, drug delivery and clinical applications , 2008, International journal of nanomedicine.

[48]  R. Löbenberg,et al.  Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review , 2007 .

[49]  Sanjay Garg,et al.  Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. , 2009, International journal of pharmaceutics.

[50]  M. Magnani,et al.  Erythrocyte-based drug delivery , 2005, Expert opinion on drug delivery.

[51]  Wei Yang,et al.  Inhaled nanoparticles--a current review. , 2008, International journal of pharmaceutics.

[52]  Shri Kant,et al.  Polymeric nanoparticulate system: a potential approach for ocular drug delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[53]  Xiangrong Song,et al.  Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. , 2004, International journal of pharmaceutics.

[54]  Zhanhu Guo,et al.  Surface functionalized alumina nanoparticle filled polymeric nanocomposites with enhanced mechanical properties , 2006 .

[55]  A. Voigt,et al.  In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells. , 2010, Small.

[56]  R. Müller,et al.  Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. , 2005, International journal of pharmaceutics.

[57]  R. Langer,et al.  Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies , 2005, Pharmaceutical Research.

[58]  David A Edwards,et al.  Bioengineering of therapeutic aerosols. , 2002, Annual review of biomedical engineering.

[59]  J. Silverman,et al.  Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) , 1999, Pharmaceutical Research.

[60]  R. O. Williams,et al.  Formulation of a protein with propellant HFA 134a for aerosol delivery. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[61]  K. Johnston,et al.  Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs , 2004, Drug development and industrial pharmacy.

[62]  Qiang Zhang,et al.  Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. , 2011, Colloids and surfaces. B, Biointerfaces.

[63]  Qiang Zhang,et al.  In vitro and in vivo antitumor activity of oridonin nanosuspension. , 2009, International journal of pharmaceutics.

[64]  Ashim K. Mitra,et al.  Recent Perspectives in Ocular Drug Delivery , 2009, Pharmaceutical Research.

[65]  Jun Li,et al.  Preparation and characterization of intravenously injectable nimodipine nanosuspension. , 2008, International journal of pharmaceutics.

[66]  Wenting Dai,et al.  Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. , 2008, International journal of pharmaceutics.

[67]  Dominique Duchêne,et al.  Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract , 1997 .

[68]  Carmen Popescu,et al.  Conversion of Nanosuspensions into Dry Powders by Spray Drying: A Case Study , 2008, Pharmaceutical Research.

[69]  Po-Chang Chiang,et al.  Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment , 2007, Nanoscale Research Letters.

[70]  K. Sigfridsson,et al.  A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[71]  C Olbrich,et al.  Formulation of amphotericin B as nanosuspension for oral administration. , 2003, International journal of pharmaceutics.

[72]  Aiguo Li,et al.  Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer , 2010, Drug development and industrial pharmacy.

[73]  D. Andes In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis , 2003, Antimicrobial Agents and Chemotherapy.

[74]  O. Kayser,et al.  The impact of nanobiotechnology on the development of new drug delivery systems. , 2005, Current pharmaceutical biotechnology.

[75]  J. Kreuter,et al.  Use of nanoparticles for cerebral cancer. , 2008, Tumori.

[76]  O. Kayser,et al.  A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. , 2001, International journal of pharmaceutics.

[77]  H. Chan,et al.  Formation, characterization, and fate of inhaled drug nanoparticles. , 2011, Advanced drug delivery reviews.

[78]  O. Kayser,et al.  Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[79]  Dianrui Zhang,et al.  Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system , 2008 .

[80]  Joseph Wong,et al.  Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. , 2007, International journal of pharmaceutics.

[81]  H. Gendelman,et al.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. , 2006, Blood.

[82]  Asgar Ali,et al.  Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[83]  E. R. Cooper,et al.  Nanoparticles: A personal experience for formulating poorly water soluble drugs. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[84]  Filippos Kesisoglou,et al.  Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.

[85]  F. Ahmad,et al.  Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[86]  J. Smart The basics and underlying mechanisms of mucoadhesion. , 2005, Advanced drug delivery reviews.

[87]  Cornelia M Keck,et al.  Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. , 2004, Journal of biotechnology.

[88]  Jean-Michel Kauffmann,et al.  The effects of excipients on transporter mediated absorption. , 2010, International journal of pharmaceutics.

[89]  A. Lundqvist,et al.  Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development , 2009, Drug development and industrial pharmacy.

[90]  S. Waldman,et al.  The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[91]  J. Engbersen,et al.  Polymeric carrier systems for siRNA delivery. , 2012, Current Topics in Medicinal Chemistry.

[92]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[93]  M. Magnani,et al.  Cell-based drug delivery. , 2008, Advanced drug delivery reviews.

[94]  J. Qiu,et al.  Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. , 2008, International journal of pharmaceutics.

[95]  K. Johnston,et al.  High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. , 2008, International journal of pharmaceutics.

[96]  Forrest M Kievit,et al.  Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. , 2011, Advanced drug delivery reviews.

[97]  Peter R. Byron,et al.  Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.

[98]  R. Budden,et al.  Experiments on the toxic, sedative and muscle relaxant potency of various drug solvents in mice. , 1979, Pharmacology & therapeutics. Part B: General & systematic pharmacology.

[99]  D. Loebenberg,et al.  Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis , 2004, Antimicrobial Agents and Chemotherapy.

[100]  S. Szefler,et al.  Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. , 1999, The Journal of allergy and clinical immunology.

[101]  A. Lamprecht,et al.  Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells , 2006 .

[102]  A. Astier,et al.  Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[103]  Kinam Park To PEGylate or not to PEGylate, that is not the question. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[104]  S. Krishnakumar,et al.  Nanotechnology in ocular drug delivery. , 2008, Drug discovery today.

[105]  G. Liversidge,et al.  Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats , 1995 .

[106]  J. Perfect,et al.  SAFETY OF AEROSOLIZED AMPHOTERICIN B LIPID COMPLEX IN LUNG TRANSPLANT RECIPIENTS12 , 2001, Transplantation.

[107]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[108]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[109]  G. Ennas,et al.  Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. , 2009, International journal of pharmaceutics.

[110]  M. Thanou,et al.  Targeting nanoparticles to cancer. , 2010, Pharmacological research.

[111]  Anna Nordmark,et al.  A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development , 2011, Drug development and industrial pharmacy.

[112]  G. Angioni,et al.  Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[113]  M. Pratter,et al.  The physiologic effects of inhaled amphotericin B. , 1995, Chest.

[114]  K. Johnston,et al.  Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. , 2007, International journal of pharmaceutics.

[115]  R. Herrmann,et al.  A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance , 2006, Investigational New Drugs.

[116]  Qiang Zhang,et al.  Preparation and antitumor study of camptothecin nanocrystals. , 2011, International journal of pharmaceutics.

[117]  R. Shegokar,et al.  Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. , 2011, International journal of pharmaceutics.

[118]  Aihua Yu,et al.  Preparation and characterization of intravenously injectable curcumin nanosuspension , 2011, Drug delivery.

[119]  Gloria Kwei,et al.  The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. , 2004, International journal of pharmaceutics.

[120]  S. Mitragotri,et al.  Identification of Peptide Ligands Facilitating Nanoparticle Attachment to Erythrocytes , 2008, Biotechnology progress.

[121]  Pardeep Gupta,et al.  Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. , 2008, International journal of pharmaceutics.

[122]  X. Wu,et al.  Nanotechnological advances for the delivery of CNS therapeutics. , 2012, Advanced drug delivery reviews.

[123]  K. Johnston,et al.  Single dose and multiple dose studies of itraconazole nanoparticles. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[124]  Q. Shi,et al.  Characterization of folate-chitosan-DNA nanoparticles for gene therapy. , 2006, Biomaterials.

[125]  C. Lipinski Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .

[126]  Huibi Xu,et al.  Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. , 2011, International journal of pharmaceutics.

[127]  Dominique Duchêne,et al.  Bioadhesion of solid oral dosage forms, why and how? , 1997 .

[128]  Jing Ma,et al.  Preparation of a chemically stable quercetin formulation using nanosuspension technology. , 2011, International journal of pharmaceutics.

[129]  J. Barré,et al.  Stealth nanoparticles coated with heparin as peptide or protein carriers , 2009, Journal of drug targeting.

[130]  K. Johnston,et al.  Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[131]  Elaine Merisko-Liversidge,et al.  Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. , 2011, Advanced drug delivery reviews.

[132]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[133]  J E Kipp,et al.  The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. , 2004, International journal of pharmaceutics.

[134]  J. Perfect,et al.  Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients , 2004, Transplantation.

[135]  R. Pignatello,et al.  Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[136]  H. Fung,et al.  Mechanisms of creatine kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol. , 1990, Journal of pharmaceutical sciences.

[137]  A F Thünemann,et al.  Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. , 2006, International journal of pharmaceutics.

[138]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[139]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[140]  F. Liu,et al.  Targeted cancer therapy with novel high drug-loading nanocrystals. , 2010, Journal of pharmaceutical sciences.

[141]  K. Korttila,et al.  Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. , 2009, Acta pharmacologica et toxicologica.

[142]  Y. Lai,et al.  Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery , 2009, Nanoscale research letters.

[143]  M. Heimesaat,et al.  SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers , 2011, Journal of drug targeting.

[144]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[145]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[146]  K. Johnston,et al.  Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. , 2007, The Journal of infection.

[147]  G. Olmos,et al.  Delivery to macrophages and toxic action of etoposide carried in mouse red blood cells. , 2003, Biochimica et biophysica acta.

[148]  P. Vavia,et al.  Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[149]  R. Alyautdin,et al.  Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles , 1997 .

[150]  Yun-Seok Rhee,et al.  Nanomedicine in pulmonary delivery , 2009, International journal of nanomedicine.

[151]  Robert J. Lee,et al.  Targeted drug delivery via folate receptors , 2008, Expert opinion on drug delivery.

[152]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[153]  G. Sharma,et al.  Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats , 2009, Pharmaceutical Research.